{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:43:29Z","timestamp":1789469009841,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.xops.2026.101323","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T23:12:14Z","timestamp":1783984334000},"page":"101323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I\/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa"],"prefix":"10.1016","volume":"6","author":[{"given":"Bill","family":"Bunnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacque L.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Birch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2026.101323_bib1","series-title":"Genetic Diseases of the Eye","first-page":"530","article-title":"Retinitis pigmentosa","author":"Birch","year":"2025"},{"issue":"1","key":"10.1016\/j.xops.2026.101323_bib2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/medicina60010189","article-title":"Retinitis pigmentosa: from pathomolecular mechanisms to therapeutic strategies","volume":"60","author":"Vingolo","year":"2024","journal-title":"Medicina (Kaunas)"},{"issue":"9","key":"10.1016\/j.xops.2026.101323_bib3","doi-asserted-by":"crossref","first-page":"4883","DOI":"10.3390\/ijms23094883","article-title":"Retinitis pigmentosa: progress in molecular pathology and biotherapeutical strategies","volume":"23","author":"Liu","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.xops.2026.101323_bib4","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/biom14080903","article-title":"Gene therapy for retinitis pigmentosa: current challenges and new progress","volume":"14","author":"Liu","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.xops.2026.101323_bib5","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.2147\/OPTH.S370032","article-title":"Current and future treatment of retinitis pigmentosa","volume":"16","author":"Cross","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.xops.2026.101323_bib6","doi-asserted-by":"crossref","first-page":"7481","DOI":"10.3390\/ijms24087481","article-title":"Retinitis pigmentosa: current clinical management and emerging therapies","volume":"24","author":"Nguyen","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.xops.2026.101323_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41433-023-02636-3","article-title":"Full-field stimulus threshold testing: a scoping review of current practice","volume":"38","author":"Shi","year":"2024","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.xops.2026.101323_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10633-009-9204-7","article-title":"Psychophysical assessment of low visual function in patients with retinal degenerative diseases (RDDs) with the Diagnosys full-field stimulus threshold (D-FST)","volume":"119","author":"Klein","year":"2009","journal-title":"Doc Ophthalmol"},{"issue":"7","key":"10.1016\/j.xops.2026.101323_bib10","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute visual function questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2026.101323_bib11","series-title":"Annual Meeting of the American Society of Gene and Cell Therapy","article-title":"Bilateral functional improvement in patients following unilateral AAV-based retinal cell delivery of a bioengineered, synthetic protein with broad-spectrum light sensitivity","author":"Mahajan","year":"2026"},{"key":"10.1016\/j.xops.2026.101323_bib12","series-title":"Annual Meeting of the Association for Research in Vision and Ophthalmology","article-title":"Contralateral transfer of AAV-MCO-010 and retinal transduction following unilateral intravitreal delivery","author":"Mohanty","year":"2026"},{"issue":"573","key":"10.1016\/j.xops.2026.101323_bib13","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"issue":"10097","key":"10.1016\/j.xops.2026.101323_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.xops.2026.101323_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10633-023-09962-7","article-title":"ISCEV and IPS guideline for the full-field stimulus test (FST)","volume":"148","author":"Jolly","year":"2024","journal-title":"Doc Ophthalmol"},{"issue":"2","key":"10.1016\/j.xops.2026.101323_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.exer.2004.09.008","article-title":"Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures","volume":"80","author":"Roman","year":"2005","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.xops.2026.101323_bib17","author":"Retina"},{"issue":"9","key":"10.1016\/j.xops.2026.101323_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","article-title":"Assessment of visual function with cotoretigene toliparvovec in X-Linked retinitis pigmentosa in the randomized XIRIUS phase 2\/3 study","volume":"131","author":"Lam","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2026.101323_bib19","series-title":"Presented at: American Academy of Ophthalmology Annual Meeting","article-title":"Efficacy and safety of MCO-010 optogenetic therapy for vision restoration in patients with severe vision loss due to RP: two-year topline results from a phase 2b\/3 randomized, sham-controlled clinical trial (RESTORE)","author":"Ho","year":"2024"},{"issue":"12","key":"10.1016\/j.xops.2026.101323_bib23","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/mt.2009.181","article-title":"Inner limiting membrane barriers to AAV- mediated retinal transduction from the vitreous","volume":"17","author":"Dalkara","year":"2009","journal-title":"Mol Ther"},{"issue":"1","key":"10.1016\/j.xops.2026.101323_bib24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ymthe.2016.10.008","article-title":"Improved intravitreal AAV-Mediated inner retinal gene transduction after surgical internal limiting membrane peeling in cynomolgus monkeys","volume":"25","author":"Takahashi","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.xops.2026.101323_bib25","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S1525-0016(16)32838-6","article-title":"Novel surgical method for intravitreal AAV administration overcomes transduction barriers in non-human Primates","volume":"24","author":"Comander","year":"2016","journal-title":"Mol Ther"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914526002617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:22:23Z","timestamp":1789464143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914526002617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666914526002617"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2026.101323","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/IIa Study of an Intravitreal Optogenetic Therapy (AGN-151597) in Patients with Advanced Retinitis Pigmentosa","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2026.101323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101323"}}